Reporter brief
Randomized trial of rapamycin versus placebo for aging effects in older adults; safety and efficacy assessed
What happened
PEARL was a prospective, double-blind, placebo-controlled randomized trial examining rapamycin's safety and efficacy in reducing clinical measures of aging in older adults. The abstract does not report the sample size, which study arms were compared, what outcome measures were used, or what effects were observed.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Healthy older adult population
- Design
- Rct
- Sample
- —
- Journal
- AgelessRx
- Published
- Jan 24, 2024
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.